Navigation Links
Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
Date:11/1/2010

kidney mass in patients with advanced chronic kidney disease, a significant unmet medical need.  Tengion has now published or presented consistently positive data on the effect of its approach on kidney function in four different animal models of chronic kidney disease. Two of the models have been conducted for a sufficiently long period of time to demonstrate durability and an impact on animal survival.

  • In October 2010, Tengion presented new research data in a podium presentation at the American Society for Transplantation's Annual Scientific Exchange in Orlando, FL.  The presentation highlighted new early data from a canine model of chronic kidney disease demonstrating promising improvements in kidney function with a regenerative autologous cellular therapy approach to increase kidney mass and improve kidney function.  Specifically, the presented data showed improvements in kidney filtration, protein balance, and weight gain in treated animals compared to a control group.  Effects in a pilot study have persisted through the first three months after treatment.  A follow-up study has demonstrated efficacy as early as seven weeks after implantation.  The studies are designed to monitor progression over a six-month period and both studies are ongoing.  Tengion expects to announce further results from this study in December 2010.
  • In September 2010, Tengion presented one-year follow-up data from the Neo-Kidney Augment program in a podium presentation at the 2nd Annual Symposium on Stem Cell Translation of the International Society for Cellular Therapy in San Francisco.  The presentation highlighted new results demonstrating success with the Company's targeted autologous cellular therapy approach to kidney regeneration in a widely accepted rodent model of obesity, diabetes and hypertension.  At one year of age, the treated animals were reported to have demonstrated improved kidney function, delayed disease pro
    '/>"/>

  • SOURCE Tengion, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
    2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
    3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
    4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
    5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
    6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
    7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
    8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
    9. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
    10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/2/2015)... today they are expanding their reach nationally by providing customers with on-site 17025 accredited pipette calibrations. ... ... ... ... Photo - http://photos.prnewswire.com/prnh/20150601/219758 ...
    (Date:6/2/2015)... 2015  CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached an agreement to settle ... Delaware Court of Chancery, which names as ... directors and officers, and names the Company as a ... re CytRx Corp. Stockholder Derivative Litigation , C.A. No. ...
    (Date:6/2/2015)... ACTON, Mass. , June 2, 2015  Psychemedics ... global leader for over twenty-five years, announced the addition ... panels. In response to growing abuse concerns, the addition ... panel and D-Amphetamine/Adderall® was added as an option to ... , Chairman and CEO stated:  "Sadly, more and more ...
    Breaking Medicine Technology:Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 2Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 3Integrated Service Solutions, Inc. Announces Nationwide Expansion for On-site Pipette Calibrations 4CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4Psychemedics Announces Addition Of FDA Cleared Drugs 2Psychemedics Announces Addition Of FDA Cleared Drugs 3
    ... Inc. (Nasdaq: BNVI ) announced today that it ... year 2010 ended September 30, 2010 on Thursday, November 11, ... to review the financial results on Thursday, November 11, 2010 ... the call by dialing (877) 317-6789 or (412) 317-6789, or ...
    ... 4, 2010 ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ... Brian M. Culley, will present at the Wall Street Analyst ... 2010 at 12:50 p.m. Eastern time, at The University Club ... a live audio webcast and slide presentation on the Company,s ...
    Cached Medicine Technology:
    (Date:6/2/2015)... Branchburg, NJ (PRWEB) June 02, 2015 ... independent verification for non-GMO products made according to ... avoidance. Verified products are produced in compliance with ... testing of all GMO risk ingredients, facility inspections ... possible standards for GMO avoidance. , “Savoury Systems ...
    (Date:6/2/2015)... (PRWEB) June 02, 2015 Consumer ... consumer organization, today announced its commitment to help ... to the use of antibiotics sicken about 2.25 ... to the Centers for Disease Control and Prevention. ... President and CEO Marta Tellado participating in the ...
    (Date:6/2/2015)... June 02, 2015 Robert LaPrade, ... Officer at the Steadman Philippon Research Institute, participated in ... for Single Sport Specialization? ” This was a collaborative ... (AOSSM) Research Committee that was recently published in the ... this project was limited, there is evidence that early ...
    (Date:6/2/2015)... While the movie box office may be ... books themselves are stepping into a new role: that ... produce educational comics in multiple languages that will explain ... - an international effort to address humanity’s most pressing ... energy, inequality, climate change and more. , “The United ...
    (Date:6/2/2015)... North Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... American publisher of audit, compliance and risk ... of a new online risk management effectiveness gap-improvement ... reduce the effect of uncertainty on objectives. Organizations ... but they improve their capabilities to do this ...
    Breaking Medicine News(10 mins):Health News:Savoury Systems International Receives Non-GMO Project Verification Continuing its Commitment to Provide Customers with Clean Label Ingredients 2Health News:Consumer Reports Aims to Stop the Spread of Superbugs 2Health News:Consumer Reports Aims to Stop the Spread of Superbugs 3Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Can Comics Help the United Nations Save the World? 2Health News:Can Comics Help the United Nations Save the World? 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4
    ... Quarter Revenue of $74.6 Million - , ... Guidance -Fourth Quarter and Full Year 2008 Highlights:- Fourth quarter ... quarter 2007- Full year 2008 total revenue of $250.1 million; ... the second half 2008 of $10 million; exceeds prior guidance ...
    ... All, Will Solve Crisis and Cut Costs OAKLAND, Calif., ... nurses today praised President Obama,s call for "comprehensive" healthcare ... emphasized that only genuine reform, as in expanding Medicare ... and rein in the skyrocketing costs that the president ...
    ... Feb. 25 Medarex, Inc. (Nasdaq: MEDX ) ... ended December 31, 2008. Medarex,s net loss for the year ... share, as compared to a net loss of $27.1 million, ... 2008 includes a gain of $151.8 million, or $1.18 per ...
    ... , , WEDNESDAY, Feb. 25 (HealthDay News) -- U.S. ... drug applications from a Ranbaxy Laboratories plant in India ... Ranbaxy, based in India, is one of the largest ... , "We took this action after it became apparent ...
    ... of Craneware,s 10th Anniversary YearATLANTA, Feb. 25 Craneware (AIM: CRW.L), ... health systems, is pleased to announce its interim results for the ... , Total of $21.8m ... 28% ...
    ... Ranbaxy has just received a letter and information ... Paonta Sahib facility have been added to a list ... "AIP". Ranbaxy will analyze the letter and other ... FDA has said it has no evidence the drugs ...
    Cached Medicine News:Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 10Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 11Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 12Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 13Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 14Health News:NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results 15Health News:Nurses Welcome President's Call for Comprehensive Health Reform 2Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 2Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 3Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 4Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 5Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 6Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 7Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 8Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 9Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 10Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 11Health News:Medarex Announces 2008 Fourth Quarter and Year End Financial Results 12Health News:FDA Halts New Applications From Indian Drug Maker's Plant 2Health News:Craneware Announces Half-Year Results 2Health News:Press Statement Issued by Ranbaxy Laboratories Limited 2
    VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
    ... tubes contain a buffered sodium ... with a citrate concentration of ... mol/l (3.8%). The mixing ratio ... to 9 parts blood. In ...
    ... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
    VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
    Medicine Products: